The Herbal Pair of Smilax Glabra Roxb. And Ficus Hirta Vahl. Improves Exercise Performance by Regulating Mitochondrial Function via the Adiponection Receptors-Mediated AMPK Signaling Pathway

Why It Matters

The findings point to a natural, plant‑based anti‑fatigue ingredient that could reshape sports‑nutrition and functional‑food markets, offering a scientifically backed alternative to synthetic performance enhancers.

Key Takeaways

• FSP improves mouse exercise endurance and glycogen storage
• Taxifolin and apigenin activate AdipoR1/AdipoR2‑AMPK pathway
• Treatment reduces lactate, oxidative stress, and systemic inflammation
• Synergistic effect observed between taxifolin and apigenin in vivo

Pulse Analysis

Exercise‑induced fatigue remains a major barrier for athletes and active consumers, and mitochondrial dysfunction is at the heart of the problem. Recent research has turned to traditional botanicals for solutions, and the herbal duo Smilax glabra and Ficus hirta—known in Chinese medicine for liver protection—has emerged as a promising candidate. By leveraging a rigorous mouse model, researchers demonstrated that the pair not only extends running time and grip strength but also accelerates lactate removal and replenishes glycogen stores, addressing the metabolic bottlenecks that cause early exhaustion.

The mechanistic breakthrough lies in the activation of adiponectin receptors AdipoR1 and AdipoR2, which cascade into heightened AMPK phosphorylation and PGC‑1α expression. This signaling axis drives mitochondrial biogenesis, improves fatty‑acid oxidation, and stabilizes cellular energy balance during intense activity. Two flavonoids, taxifolin and apigenin, were pinpointed as the principal effectors; docking studies confirmed strong binding to the receptors, and in‑vivo experiments showed a synergistic boost when both compounds are present. Such a dual‑component approach mirrors the holistic philosophy of herbal medicine while delivering a clear molecular target for product developers.

From a market perspective, the data open a pathway for premium, evidence‑based sports supplements that capitalize on the growing consumer demand for natural performance enhancers. Companies can formulate standardized extracts containing quantified taxifolin and apigenin, positioning them alongside creatine and beta‑alanine but with a distinct anti‑oxidative and anti‑inflammatory profile. Regulatory hurdles remain, as claims must be substantiated in human trials, yet the pre‑clinical evidence provides a compelling foundation for investment, partnership, and further clinical research aimed at translating these findings into commercially viable, FDA‑compliant products.